Open Access
ISSN:0965-0407 (print)
ISSN:1555-3906 (online)
Publication Frequency:Monthly
Oncology Research is committed to publishing high-quality, innovative research that is focused on the entire range of basic, translational, and clinical cancer research, with a particular interest in cancer therapeutics, providing a new platform for the understanding, prevention, diagnosis, and treatment of cancer.
Science Citation Index Expanded (Clarivate Analytics): 2025 Impact Factor: 4.6; Scopus CiteScore (Impact per Publication 2025): 4.1; SNIP (Source Normalized Impact per Paper 2025): 0.767; Embase; PubMed Central; MEDLINE; EBSCO; Google Scholar; Proquest; Portico, etc.
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.081755 - 13 August 2026
（This article belongs to the Special Issue: Advances in Cancer Therapeutics)
Abstract Background: Vulvar squamous cell carcinoma (VSCC) is a rare, but increasingly prevalent malignancy with limited therapeutic options in the advanced disease state. Cisplatin-based chemoradiation remains the standard of care but is constrained by cumulative toxicity. Precancerous lesions, including high-grade squamous intraepithelial lesions (HSIL) and differentiated vulvar intraepithelial neoplasia (dVIN), similarly require effective yet tolerable treatments. Low-thermal Argon plasma devitalization (ltAPD), a source of reactive oxygen and nitrogen species (RONS), has emerged as a promising approach for redox-based tumor modulation. This study aimed to evaluate the anti-tumor efficacy of two plasma modalities, plasma-treated solution (PTS) and plasma-treated… More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082155 - 13 August 2026
（This article belongs to the Special Issue: Advances in Cancer Therapeutics)
Abstract Cytoskeletal reorganization is fundamental to essential cellular processes, including shape maintenance, migration, adhesion cytokinesis, and phagocytosis, and its dysregulation is a hallmark of tumor progression. In cancer cells, altered cytoskeletal dynamics promote invasion and genomic instability resulting from mitotic defects. The actin and microtubule cytoskeletons are highly dynamic polymer networks that organize intracellular architecture, establish polarity, and generate the mechanical forces required for cell division and motility. Their dysregulation disrupts normal cell behavior and facilitates tumor invasion and metastasis. The cytoskeleton therefore represents a key source of potential therapeutic targets for inhibiting metastatic dissemination. This More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.079753 - 13 August 2026
Abstract This article systematically elaborates on the dual role of DNA methylation in the initiation and progression of gastric cancer and its potential clinical applications in precision oncology. As a core epigenetic mechanism, DNA methylation drives the multistage development of gastric cancer through the coordinated dysregulation of genome-wide hypomethylation and promoter-specific hypermethylation, playing a key role in chronic inflammation and epigenetic reprogramming, particularly in the context of Helicobacter pylori infection. The article focuses on analyzing the central pathogenic mechanisms of DNA methylation, including the silencing of tumor suppressor genes, induction of genomic instability, promotion of the CpG More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083359 - 13 August 2026
（This article belongs to the Special Issue: Targeting the Tumor Microenvironment: Emerging Insights into Cancer Progression and Therapeutics)
Abstract Ovarian cancer is the most lethal gynecological malignancy, with most patients diagnosed at an advanced stage and eventually relapsed after post-platinum-taxane chemotherapy. High intratumoral heterogeneity, extensive peritoneal dissemination, and acquired chemoresistance continue to restrict the clinical benefits of current therapeutic strategies. Increasing evidence indicates that ovarian cancer stem cells (OCSCs), a rare but highly plastic subpopulation characterized by self-renewal, multilineage differentiation, quiescence, tumor-initiating capacity, and intrinsic stress tolerance, play pivotal roles in tumor initiation, metastasis, recurrence, and therapeutic resistance. In this review, we systematically summarize current knowledge regarding the identification and functional characterization of OCSCs More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083636 - 13 August 2026
（This article belongs to the Special Issue: Breaking the Bottleneck of Therapeutic Resistance in Solid Tumors: Emerging Technologies, Novel Targets, and Innovative Strategies)
Abstract Breast cancer ranks first in global cancer incidence. Due to its high heterogeneity, cancer cells often develop drug resistance during metastasis, leading to therapeutic challenges and poor prognosis. Consequently, breast cancer organoid models have emerged, which can effectively recapitulate the tumor microenvironment and serve as important tools for investigating the mechanisms underlying breast cancer initiation and progression. Breast cancer organoids exhibit interactions between cells and the extracellular matrix (ECM) while retaining the heterogeneity of the original tumor cells. Owing to these advantages, such models have been widely applied in studies of tumor pathogenesis, disease modeling,… More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083919 - 13 August 2026
（This article belongs to the Special Issue: Next-Generation Oncology: Unearthing and Validating Novel Therapeutic Targets)
Abstract Despite the potential of current cancer immunotherapies, tumor cells frequently evade immune surveillance by forming an immunosuppressive microenvironment, leading to treatment resistance. Current inquiry positions the sympathetic nervous system (SNS) at the forefront of tumor immunology as a critical driver of this immune evasion. This review delineates the cellular pharmacology of SNS-mediated immune regulation across the tumor ecosystem. Operating predominantly through the cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) signaling axis, the SNS engages in bidirectional regulation with immune cells of the tumor microenvironment (TME). Norepinephrine and epinephrine interact with β2-adrenergic receptors (β2-ARs), triggering G-protein dissociation, adenylyl… More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.080113 - 13 August 2026
（This article belongs to the Special Issue: Advances in Pathology, Early Diagnosis and Therapeutic Strategies for Breast Cancer)
Abstract Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by poor clinical outcomes. Owing to the absence of estrogen receptors, progesterone receptors, and Human Epidermal Growth Factor Receptor 2 (HER2) expression, TNBC shows limited responsiveness to conventional endocrine and targeted therapies. This subtype exhibits strong heterogeneity, a high propensity for metastasis, and a tendency to develop acquired drug resistance. Its survival and progression largely rely on non-classical signaling pathways, including Epidermal growth factor receptor (EGFR), Phosphoinositide 3-kinase/Protein Kinase B (PI3K/AKT), and Notch, which collectively impose substantial challenges to clinical management. In recent… More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.081222 - 13 August 2026
Abstract Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive malignancy characterized by a poor long-term prognosis. Aberrant activation of the canonical Wnt/β-catenin pathway serves as a central oncogenic driver in ESCC, with large-scale genomic analyses revealing that most patients harbor alterations in pathway-associated genes. This signaling axis orchestrates a wide array of malignant phenotypes, including tumor proliferation, invasion, epithelial-mesenchymal transition (EMT), cancer stemness, and therapeutic resistance. Therefore, this review aims to provide a comprehensive synthesis of the multifaceted crosstalk between various ncRNA classes and the Wnt/β-catenin axis, highlighting their roles in ESCC progression and their… More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084736 - 13 August 2026
（This article belongs to the Special Issue: Advancing Cellular Therapeutics in Oncology: Innovations, Challenges, and Clinical Translation)
Abstract Cervical cancer, particularly its advanced stages, requires novel therapeutic paradigms. Cellular immunotherapy exploits the constitutive expression of HPV E6/E7 oncoproteins as near-ideal tumor-specific antigens. This review systematically evaluates four principal platforms under investigation: tumor-infiltrating lymphocytes (TILs), TCR-engineered T cells, CAR-T cells, and CAR-NK cells. We critically analyze the preclinical rationale, clinical trial landscape, safety considerations, and manufacturing challenges for each modality. TIL therapy has achieved durable complete responses and an FDA Breakthrough Therapy designation. TCR-T cells enable precise targeting of intracellular viral epitopes but are HLA-restricted. CAR-T cells offer potent, MHC-independent recognition, yet face on-target/off-tumor More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084411 - 13 August 2026
Abstract Intraductal Papillary Mucinous Neoplasm (IPMN) is a major precancerous lesion of pancreatic ductal adenocarcinoma. Accurate risk stratification of IPMN is key to preventing and controlling pancreatic cancer. At present, clinicians mainly grade IPMN following the Kyoto consensus guidelines, together with imaging examinations and traditional serum biomarkers like CA19-9 and CEA. This review unveils the latest research progress of non-invasive blood biomarkers for the grading of IPMN, including the diagnostic performance, molecular mechanisms, and current clinical translation of several types of markers. ApoAII has already been applied in clinical practice, and miRNA combinations, circulating cell-free DNA… More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083902 - 13 August 2026
（This article belongs to the Special Issue: Molecular Targeting Therapy for Anticancer Treatment)
Abstract Nucleocytoplasmic transport (NCT) regulates the spatial distribution of proteins and RNA between the nucleus and cytoplasm. NCT dysregulation can mislocalize tumor suppressors, DNA-repair factors, transcription factors, and drug targets in cancer. In this review, we conceptualize NCT-dependent protein mislocalization as a spatial regulatory framework for anticancer drug resistance, rather than as a catalogue of transport components. We systematically discuss how nuclear pore complex (NPC) remodeling, transport-receptor imbalance, post-translational modification (PTM)-regulated cargo routing, signaling-NCT crosstalk, nuclear localization signal/nuclear export signal (NLS/NES) alterations, and tumor microenvironmental pressures jointly drive aberrant nucleocytoplasmic distribution. These processes can further regulate… More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083159 - 13 August 2026
Abstract Mitochondria are central regulators of cellular metabolism and survival and play a pivotal role in cancer development and progression through the production of reactive oxygen species (ROS), control of calcium homeostasis, regulation of autophagy, and modulation of cell death pathways. Mitochondria-derived ROS (mtROS) act as signaling mediators that influence tumor initiation, proliferation, metabolic reprogramming, metastasis, and therapeutic resistance by altering redox homeostasis, damaging mitochondrial DNA, and reshaping the tumor microenvironment. In addition to meeting the bioenergetic and biosynthetic requirements of rapidly proliferating cancer cells, mitochondrial metabolism modulates immune responses and supports cancer cell adaptation to More >
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085967 - 13 August 2026
Abstract Triple-negative breast cancer (TNBC) is characterized by marked metabolic plasticity, spatial heterogeneity, and therapy-induced adaptive remodeling. However, TNBC metabolism is often discussed as isolated pathways, making it difficult to link metabolic rewiring to immune exclusion, drug-tolerant persister cells, and treatment windows. Here, we propose a functional metabolic operating-state framework to organize recurrent adaptive programs in TNBC. Importantly, the S1–S5 framework is not a clinically validated subtype classification, but a set of coexisting and reversible operating states shaped by microenvironmental and therapeutic pressures. S1 represents a glycolysis–lactate/acidosis barrier; S2 denotes fatty acid oxidation (FAO)/oxidative phosphorylation (OXPHOS)-supported… More >
Graphic Abstract
Open Access
REVIEW
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082432 - 13 August 2026
（This article belongs to the Special Issue: Advances in Genitourinary Cancer)
Abstract In renal cell carcinoma (RCC), alterations in cellular metabolism are a defining feature, among which impaired mitochondrial function stands out as a key factor influencing both tumor aggressiveness and patient responses to therapy. The aim of this review is to systematically synthesize current knowledge on the role of mitochondrial dysfunction in RCC pathogenesis and to explore emerging therapeutic strategies targeting mitochondrial vulnerabilities. This comprehensive analysis examines the integrated dysregulation of core mitochondrial processes—bioenergetic metabolism, organelle dynamics, programmed cell death pathways, redox homeostasis, and selective autophagy—in driving RCC pathogenesis. Our synthesis reveals how genetic drivers, molecular… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.080964 - 13 August 2026
（This article belongs to the Special Issue: Precision Beyond Progression: Real-World Evidence and Dynamic Prognostic Markers in Refractory Metastatic Colorectal Cancer)
Abstract Background: Trifluridine/tipiracil (T) is a standard treatment for refractory metastatic colorectal cancer (mCRC). In randomized trials, treatment-emergent neutropenia has been associated with improved outcomes, suggesting a potential link with drug activity. However, evidence from routine clinical practice remains limited. This sub-analysis of the multicenter ReTrITA study evaluated the association between severe neutropenia and clinical outcomes in a real-world setting. Methods: Patients with refractory mCRC treated with T within the ReTrITA cohort were included. Patients were stratified according to the occurrence of grade 3–4 neutropenia. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083206 - 13 August 2026
（This article belongs to the Special Issue: Advances in Liver Cancer: Novel Therapeutics and Biomarkers for HCC and CCA)
Abstract Introduction: Durvalumab plus tremelimumab (Durva/Treme) improved survival in the HIMALAYA trial for unresectable hepatocellular carcinoma (HCC), but real-world evidence remains limited. This study aimed to evaluate clinical outcomes of Durva/Treme in routine practice. Methods: This retrospective multicenter study included patients with unresectable or advanced HCC who received Durva/Treme through the Expanded Access Program in Thailand between August 2023 and November 2025. Treatment outcomes and adverse events (AEs) were analyzed and descriptively compared with the HIMALAYA trial. Results: Fifty patients were included; median age was 62 years and 80% were male. Etiologies included hepatitis B (44%), hepatitis C… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.080527 - 13 August 2026
Abstract Background: Interleukin-31 receptor alpha (IL31RA) has been implicated in cancer progression and tumor cell migration, but its genetic associations across cancers remain unclear. This study aimed to examine IL31RA polymorphisms in relation to lymph node involvement in oral cavity squamous cell carcinoma (OCSCC). Methods: In this case-control study, 2845 participants were enrolled, including 1352 patients with OCSCC and 1493 cancer-free controls. Associations between IL31RA SNPs and OCSCC susceptibility and clinicopathological characteristics were evaluated. Functional analyses, including cell migration assays, together with bioinformatic database analyses, were performed to investigate the biological significance of IL31RA and genotype–expression correlations. Logistic… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.079551 - 13 August 2026
（This article belongs to the Special Issue: Precision Oncology: Targeted Therapies and Tumor Microenvironment)
Abstract Objectives: Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) necessitate the discovery of novel biomarkers for prognostic and therapeutic advancement. This study aims to evaluate the clinical significance of ubiquitin-conjugating enzyme E2C (UBE2C) and its association with the tumor microenvironment (TME) in CESC. Methods: We meticulously sourced CESC data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO), leveraging cutting-edge techniques including single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics. Through multifaceted data analysis, we endeavored to unravel the intricate role and potential value of UBE2C in… More >
Graphic Abstract
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083962 - 13 August 2026
（This article belongs to the Special Issue: Molecular Targeting Therapy for Anticancer Treatment)
Abstract Objectives: Temozolomide (TMZ) resistance remains a major challenge in glioblastoma (GBM) treatment. This study investigated the role of miR-152-3p and its downstream target, transforming growth factor-α (TGF-α), in regulating TMZ sensitivity in GBM. Methods: Public GEO and CGGA datasets were analyzed to evaluate the expression and prognostic significance of miR-152-3p. TMZ-resistant GBM cell lines (U87MGR and DBTRG-05MGR) were established by continuous TMZ exposure. Gain- and loss-of-function experiments were performed using miR-152-3p mimics and inhibitors. Cell viability, apoptosis, and TGF-α expression were assessed by MTT, qRT-PCR, and Western blot analyses. Results: miR-152-3p expression was significantly decreased in recurrent… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085356 - 13 August 2026
Abstract Background: Adenoid cystic carcinoma (ACC) of the breast is a rare triple-negative malignancy with an indolent clinical course distinct from conventional triple-negative breast cancer (TNBC). Optimal management remains undefined due to limited prospective data. This study aimed to characterise the clinicopathological features, treatment patterns, and long-term outcomes of breast ACC at a high-volume specialist centre, contributing real-world evidence to inform management in the absence of prospective trial data. Methods: A single-institution retrospective cohort study was conducted of 24 patients with histopathologically confirmed breast ACC treated at The Royal Marsden NHS Foundation Trust between 2000 and… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082424 - 13 August 2026
（This article belongs to the Special Issue: Machine Learning for Precision Oncology: From Bench to Bedside)
Abstract Background: Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are B-cell malignancies with distinct cellular origins and microenvironmental dependencies. We aimed to identify concordant transcriptomic signatures and candidate transcriptional regulatory features between CLL CD19-positive B cells and MM-associated bone marrow-derived mesenchymal stromal cells (MSCs). Methods: Public Gene Expression Omnibus bulk RNA sequencing datasets were analyzed separately within each context using DESeq2. Differentially expressed genes (DEGs) were defined using adjusted p-value < 0.05 and absolute log2 fold change > 1. Cross-disease analyses assessed overlap, directionality, log2 fold-change concordance, expressed-gene background-adjusted enrichment, coexpression structure, and transcription factor annotation. Results: We… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083437 - 13 August 2026
（This article belongs to the Special Issue: Novel Biomarkers and Treatment Strategies in Solid Tumor Diagnosis, Progression, and Prognosis (Ⅱ))
Abstract Objectives: Gastric cancer remains a major global health burden, and robust biomarkers are needed to improve risk stratification. Although peptidyl-prolyl isomerase B (PPIB) has been suggested as a potential oncogenic factor, its clinical utility in gastric cancer remains unclear. This study aims to evaluate the clinicopathological and prognostic significance of PPIB mRNA expression and delineate its functional role in driving tumor progression. Methods: PPIB mRNA expression was evaluated in a retrospective cohort of 497 gastric cancer patients using RNAscope in situ hybridization and digital image analysis. Functional roles and underlying mechanism were assessed through siRNA-mediated knockdown, plasmid-driven overexpression,… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.085229 - 13 August 2026
（This article belongs to the Special Issue: RAS Driven Oncogenesis and the Future of Combination Therapy in Solid Tumors)
Abstract Background: Anti-EGFR therapy is widely used as first-line treatment for RAS wild-type metastatic colorectal cancer (mCRC), particularly in patients with left-sided tumors. In liver-limited disease, maximizing tumor shrinkage may facilitate conversion to resectability; however, comparative real-world evidence among panitumumab, cetuximab, and bevacizumab remains limited. This study aimed to compare the clinical outcomes of these biologic agents in patients with RAS wild-type mCRC. Methods: We retrospectively analyzed 241 patients with RAS wild-type mCRC treated with first-line chemotherapy plus panitumumab (n = 76), cetuximab (n = 80), or bevacizumab (n = 85) between 2016 and 2024. Outcomes included depth of response… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082652 - 13 August 2026
（This article belongs to the Special Issue: Identification of potential targets and biomarkers for cancers and the exploration of novel molecular mechanisms of tumorigenesis and metastasis)
Abstract Background: As a core component of the immunoproteasome, the β1i subunit (proteasome 20S subunit beta 9, PSMB9) is involved in antigen processing and presentation and regulates anti-tumor immune responses. PSMB9 is aberrantly overexpressed in colorectal cancer. However, the precise mechanisms through which PSMB9 contributes to the initiation, progression, and immune regulation of colorectal cancer remain unclear. This study aims to investigate the expression characteristics and biological functions of PSMB9 in colorectal cancer, and to further elucidate the molecular pathways underlying its role in colorectal cancer initiation and progression. The findings are expected to provide a theoretical… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084378 - 13 August 2026
Abstract Background: Patients with refractory metastatic colorectal cancer (mCRC) face limited treatment options after failure of standard therapies. This single-arm, phase II study aimed to evaluate the efficacy and safety of rechallenge strategies using previously effective regimens in late-line mCRC. Methods: Patients who progressed after ≥2 lines of prior chemotherapy, with a prior progression-free survival (PFS) ≥4 months and a ≥4-month treatment-free interval on that regimen were enrolled. Patients received rechallenge chemotherapy (oxaliplatin-, irinotecan-, or raltitrexed-based) with or without targeted agents (bevacizumab or cetuximab). Primary endpoint was investigator-assessed PFS. Secondary endpoints included objective response rate (ORR), disease… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082815 - 13 August 2026
（This article belongs to the Special Issue: Advancements in Hepatocellular Carcinoma Treatment)
Abstract Background: Invariant natural killer T (iNKT) cells show promise as immunotherapeutic agents for solid tumors, and our prior study demonstrated that combining iNKT-cell therapy with transarterial chemoembolization (TACE) achieved a 58.3% objective response rate (ORR) in hepatocellular carcinoma (HCC). This study further examines iNKT-mediated immune modulation of post-TACE survival dynamics and associated prognostic biomarkers. Methods: Clinical data and peripheral blood samples were obtained from 77 HCC patients in Beijing you’an Hospital between 2018–2023, including 38 receiving TACE alone and 39 receiving combined iNKT-cell/TACE therapy. Serial measurements included: Hematological parameters; Liver function tests [alanine aminotransferase (ALT), aspartate… More >
Open Access
ARTICLE
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.081656 - 13 August 2026
（This article belongs to the Special Issue: Innovative Diagnostic Strategies in Gynecological Cancer Research)
Abstract Objectives: Given the increasing drug resistance in ovarian cancer (OC), the use of poly ADP-ribose polymerase inhibitors (PARPi) for treating homologous recombination repair defects (HRD) has encountered new challenges. MicroRNA320e (miR-320e) exerts a negative regulatory role in the progression of multiple cancers. This study aimed to investigate the association between miR-320e and drug resistance in ovarian cancer. Methods: The Cell Counting Kit-8 (CCK-8) assay, migration and invasion assays, and colony formation assay were employed to evaluate the proliferation, migration, and invasion abilities of cells. Western blot (WB) analysis was used to verify the expression levels… More >
Open Access
CASE REPORT
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083193 - 13 August 2026
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract Background: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and remains a leading cause of cancer-related mortality worldwide due to frequent recurrence and early metastasis. While immune checkpoint inhibitor (ICPI)-based regimens have revolutionized the treatment landscape for advanced HCC, clinical evidence regarding the safety and efficacy of ICPI rechallenge following disease progression or severe immune-related adverse events (irAEs) remains sparse. This report describes a case of prolonged disease stability achieved through sequential immunotherapy using durvalumab and tremelimumab (Durva/Treme) after prior ICPI failure and high-grade toxicity. Case Description: A 65-year-old male with recurrent stage IV… More >
Open Access
RETRACTION
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.090478 - 13 August 2026
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.090479 - 13 August 2026
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.090481 - 13 August 2026
Abstract This article has no abstract. More >
Login
Register
Submit a Paper
Propose a Special lssue
